Cytokine gene polymorphisms in chronic hepatitis B: A step up the immunology ladder

American Journal of Gastroenterology

Volumn 98, Issue 1, 2003, Pages 6-8

  Wai, Chun T ^a   Fontana, Robert J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC HEPATITIS; CONTAMINATION; EDITORIAL; GENETIC POLYMORPHISM; HELPER CELL; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS TRANSMISSION;

EID: 0037256521     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07169.x     Document Type: Editorial

References (22)

1. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: A global perspective. Vaccine 1999;17:1730-3.
2. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Semin Liv Dis 1991;11:84-92.
3. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen hepatitis in Greek adults. Gastroenterology 1987;92:1844-50.
4. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus genotype influence the clinical outcome of HBV infection? J Viral Hepatitis 1999;6:299-304.
5. Webster GJ, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 2000;32:1117-24.
6. Chisari FV. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
7. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients, recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.
8. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
9. Lohr H, Gerken G, Schlicht H, et al. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993;168:1133-9.
10. Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997;112:193-9.
11. Livingston BD, Alexander J, Crimi C, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999;162:3088-95.
12. Thursz MR, Kwiatkowski D, Alsopp CEM, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-9.
13. Thursz M. MHC and the viral hepatitides. Quart J Med 2001; 94:287-91.
14. Ben Ari Z, Mor E, Kfir B, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-150.
15. Bidwell JL, Wood NA, Morse HR, et al. Human cytokine gene nucleotide sequence alignments. Eur J Immunogenet 1998;25:83-265.
16. Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-B1 gene with the rate of progression of HCV induced liver fibrosis. Clin Chim Acta 2002;316:83-94.
17. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-33.
18. Kohler T, Kruger A, Gerken G, et al. A tumor necrosis factor-alpha (TNFa) promoter polymorphism is associated with chronic hepatitis B. Clin Exp Immunol 1998;111:579-82.
19. Pravica V, Asderakis A, Perrey C, et al. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur J Immunogenet 1999;26:1-3.
20. DiBisceglie AM, Rustgi VK, Kassianides C, et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990;11:266-70.
21. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. Br J Clin Invest 1998;102:968-75.
22. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001;33:963-71.